Mitchell F. Brin Archives

Physical Address

304 North Cardinal St.
Dorchester Center, MA 02124

Summary and key features In 2002 BOTOX® Cosmetic (onabotulinumtoxinA) became the first botulinum neurotoxin FDA approved for the management of facial lines, introducing a new chapter in aesthetic dermatology. Following local injection into muscles, onabotulinumtoxinA inhibits the release of acetylcholine…

Update on noncosmetic uses of botulinum neurotoxins

Summary and key features Botulinum neurotoxin type A (BoNT/A) was first used clinically for the ophthalmic conditions of strabismus and blepharospasm. Over the years, the number of medical conditions for which BoNT/A is used has grown based on its local…

Tag Mitchell F. Brin

Pharmacology of BOTOX® cosmetic

Update on noncosmetic uses of botulinum neurotoxins